Genetics of retinal degenerative diseases
=========================================

The retina is our window to the outside world and is the site of capture, integration and processing of visual information. The vertebrate retina consists of a retinal pigment epithelium (RPE) monolayer, Müller glial cells, and six major types of neurons (Figure [1](#F1){ref-type="fig"}a) \[[@B1],[@B2]\]. In mouse and human retinas, rods constitute over 95% of the photoreceptors and are responsible for night vision; whereas different cone sub-types (red, long wave-length (L); green, medium wave-length (M); and blue, short wave-length (S)) are associated with daylight vision, color perception and high visual acuity \[[@B3],[@B4]\]. The distribution of rod and cone photoreceptors is not uniform in the retina; for example, in humans, the central part of the retina (fovea) and a 6 mm^2^ cone-rich area around the fovea (macula) are responsible for high-resolution central vision (Figure [1](#F1){ref-type="fig"}b) \[[@B5]\]. Rhodopsin is the visual pigment in the rods, whereas the three kinds of cones in humans contain a distinct visual pigment (L-, M- and S-opsin in L, M, and S-cones, respectively) \[[@B4]\]. Development and homeostasis in the retina must be stringently controlled for normal vision \[[@B6]\].

![**Structure of the retina. (a)** Schematic organization of retinal circuits. The vertebrate retina consists of six major types of neurons - rod and cone photoreceptors, horizontal, bipolar, amacrine and ganglion cells. The rod and cone photoreceptors are specialized light-sensing neurons, which capture photons and transduce visual signals to the inner retina. The RPE serves as a barrier between the choroidal capillaries and the neural retina and is crucial for photoreceptor survival. Bipolar cells relay signals to the amacrine and ganglion cells through synapses in the inner plexiform layer. Ganglion cell axons project towards the optic nerve head and carry signals to the brain. **(b)** Ocular fundus photograph of a healthy retina showing retinal blood vessels, optic disc, macula (5 to 6 mm diameter), and fovea (central pit of the macula). Photograph provided by Dr Emily Chew (National Eye Institute, National Institutes of Health, Bethesda, MD).](gm488-1){#F1}

The dysfunction or death of retinal photoreceptors is the primary cause of vision loss in the majority of retinal degenerative diseases (RDDs) \[[@B7],[@B8]\], which are clinically and genetically heterogeneous. In general, loss of photoreceptors in the macular region is termed macular degeneration and results in central vision defects. By contrast, the loss of peripheral vision - for example, in retinitis pigmentosa (RP) - generally starts with rod dysfunction or death that is followed by cone degeneration. RDDs are associated with a diverse spectrum of phenotypes. Some, such as RP, congenital and early-onset retinal degeneration including Leber congenital amaurosis (LCA), and cone-rod dystrophies, are monogenic and non-syndromic. Some syndromic diseases, including Bardet-Biedl syndrome (BBS) and Usher syndrome, exhibit a highly penetrant retinal degeneration phenotype with multiple affected tissues and are also monogenic. Other RDDs, such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy, are complex multifactorial entities.

Monogenic RDDs, by definition, are often caused by mutations in a single gene and have a Mendelian pattern of inheritance (dominant, recessive, or X-linked). Genetic-linkage studies in large pedigrees have led to the identification of almost 200 causative genes \[[@B9]\]. Genetic defects in monogenic RDDs are highly penetrant, with little influence of non-genetic factors; nevertheless, clinical severity has often been difficult to correlate to genetic mutation because of variable penetrance, mutations in more than one gene, or modifier variants. The clinical manifestations in complex multifactorial RDDs result from the interplay among multiple susceptibility genes and epigenetic and/or environmental factors; therefore, conventional linkage and positional cloning methods have not been very effective in identifying the underlying genetic cause(s). Candidate gene and genome-wide association studies (GWAS) have been successful in identifying susceptibility loci for complex RDDs. A recent meta-analysis of GWAS discovered at least 19 genes and associated cellular pathways for AMD pathogenesis; these included the complement system (*CFH*, *C2*/*CFB*, *C3* and *CFI*), the high-density lipoprotein pathway (*LIPC* and *CETP*), the extracellular or collagen matrix pathway (*TIMP3*, *COL8A1*and *COL10A1*) and the angiogenesis signaling pathway (*VEGFA*) \[[@B10]\]. Several loci have also been identified for primary open angle glaucoma \[[@B11]-[@B13]\] and diabetic retinopathy \[[@B14]\]. The associated alleles do not, however, specify causality, and further genetic and functional dissection of susceptibility loci will be crucial for understanding their roles in disease pathogenesis.

The discovery of new RDD genes helps in the elucidation of the molecular pathways that underlie retinal development and homeostasis, and in delineating the genetic underpinnings of the degenerative process. Several recent reviews have provided excellent synopses of the genetic and biological features of human RDDs \[[@B7],[@B8],[@B15]-[@B18]\]. We therefore focus on recent advances in next-generation sequencing (NGS) methods \[[@B19]\] (Boxes 1 and 2) that have provided an unprecedented opportunity for the unbiased discovery of genes and causal variants, and for the comprehensive dissection of the genetic architecture of RDDs. We also highlight the merits and limitations associated with different NGS methods, and present a framework for integrative analyses to elucidate a more complete, multidimensional view of genomic function in retinal health and diseases. Finally, we discuss the progress and challenges in the application of NGS approaches for diagnosis and management of RDDs.

NGS approaches for gene identification in Mendelian RDDs
========================================================

Extensive genetic and clinical heterogeneity is observed in RDDs that have Mendelian inheritance. Although almost 200 genes have been identified, the genetic defects in many patients are still unknown. NGS offers a rapid, high-throughput and cost-effective approach to identify mutations underlying monogenic disorders.

Whole-exome sequencing
----------------------

A majority of Mendelian diseases are caused by highly penetrant mutations that disrupt protein coding or splice site sequences. Conventional methods of gene identification involve linkage analysis followed by sequencing of candidate genes in the critical linked region. However, small pedigrees and simplex cases (Box 1) with uncertain inheritance patterns make it difficult to identify genetic defects using the positional-candidate strategy. Whole-exome sequencing (WES) involves the capture and sequencing of all coding exons (1 to 2% of the whole genome) (Box 1) and has become an ideal choice for Mendelian disease gene discovery with or without prior linkage information \[[@B20]-[@B24]\] (Figure [2](#F2){ref-type="fig"}). A majority of commercially available exome capture kits target with high-confidence a subset of genes annotated by the Consensus Coding Sequence (CCDS) project \[[@B25]\] and the RefSeq collection \[[@B26]\]. Ever since it was first described in 2009 as proof-of-concept for Freeman-Sheldon syndrome \[[@B21]\], several studies have successfully employed WES for identifying dozens of genes in inherited diseases. With regard to retinal phenotypes, it was first employed to study an Ashkenazi Jewish family, in which WES of three affected siblings revealed a mutation in a novel gene, *DHDDS*, as a cause of RP \[[@B27]\]. Table [1](#T1){ref-type="table"} provides a summary of published reports of novel retinal disease genes discovered by WES.

![**Strategies for the identification of disease-causing variants in Mendelian diseases.** Linkage or homozygosity mapping analysis can serve as the starting point in mutation identification by NGS. If linkage is conclusive (LOD score ≥3), linkage can be analyzed using a targeted re-sequencing approach. In cases of multiple suggestive linkage peaks (LOD score \<3), whole exome/genome or candidate exome capture will be more suitable. Filtration and prioritization of variants can be customized depending on the availability of genetic information and NGS data. 1000G, 1,000 Genomes; dbSNP, Single Nucleotide Polymorphism database; EVS/EPS, Exome Variant Server (EVS) for the NHLBI Exome Sequencing Project (ESP); SIFT, sorting intolerant from tolerant.](gm488-2){#F2}

###### 

List of novel genes identified in retinal and macular degeneration using next-generation sequencing approaches

  **Method**                                     **Disease**                 **Gene symbol**             **Inheritance**                            **Aberration type**    **Reference(s)**
  ---------------------------------------------- --------------------------- --------------------------- ------------------------------------------ ---------------------- ------------------
  **Whole-exome sequencing**                     Retinitis pigmentosa (RP)   *DHDDS*                     Recessive                                  Missense               \[[@B27]\]
  *MAK*                                          Recessive                   Alu insertion               \[[@B28]\]                                                        
  *GNPTG*                                        Recessive                   6-bp deletion               \[[@B29]\]                                                        
  *EMC1*                                         Recessive                   Missense                    \[[@B30]\]                                                        
  *GPR125*                                       Recessive                   Frame-shift, splice-site    \[[@B30]\]                                                        
  *KIAA1549*                                     Recessive                   Frame-shift                 \[[@B30]\]                                                        
  *ARL2BP*                                       Recessive                   Splice-acceptor, missense   \[[@B31]\]                                                        
  Leber congenital amaurosis (LCA)               *NMNAT1*                    Recessive                   Missense and truncation                    \[[@B32]-[@B35]\]      
  *KCNJ13*                                       Recessive                   Truncation                  \[[@B36]\]                                                        
  *DTHD1*                                        Recessive                   Missense                    \[[@B30]\]                                                        
  Congenital stationary night blindness (CSNB)   *LRIT3*                     Recessive                   Missense and truncation                    \[[@B37]\]             
  *GPR179*                                       Recessive                   Missense and truncation     \[[@B38]\]                                                        
  Ciliopathy with skeleton abnormality           *WDR19*                     Recessive                   Missense and truncation                    \[[@B39]\]             
  High myopia                                    *ZNF644*                    Dominant                    Missense                                   \[[@B40]\]             
  Bardet-Biedl syndrome (BBS)                    *LZTFL1*                    Recessive                   Truncation                                 \[[@B41]\]             
  Nephronophthisis with retinal degeneration     *ZNF423* and *CEP164*       Recessive                   Missense, truncation, loss of stop codon   \[[@B42]\]             
  Usher syndrome                                 *HARS*                      Recessive                   Missense                                   \[[@B43]\]             
  Benign fleck retina                            *PLA2G5*                    Recessive                   Missense and truncation                    \[[@B44]\]             
  Cone-rod dystrophy                             *RAB28*                     Recessive                   Truncation                                 \[[@B45]\]             
  *ACBD5*                                        Recessive                   Frame-shift                 \[[@B30]\]                                                        
  *C21orf2*                                      Recessive                   Frame-shift                 \[[@B30]\]                                                        
  Knobloch syndrome and retinal dystrophy        *ADAMTS18*                  Recessive                   Missense                                   \[[@B46],[@B47]\]      
  **Targeted sequencing**                        RP, cone-rod dystrophy      *C8orf37*                   Recessive                                  Truncation             \[[@B48]\]
  AMD                                            *CFH*                       Dominant                    Missense                                   \[[@B49]\]             
  *CFI*                                          Dominant                    Missense                    \[[@B50]\]                                                        
  Usher syndrome                                 *ABHD12*                    Recessive                   Truncation                                 \[[@B51]\]             
  CSNB                                           *GPR179*                    Recessive                   Large insertion                            \[[@B52]\]             
  X-linked RP                                    *OFD1*                      X-linked                    Intronic mutation                          \[[@B53]\]             
  Jobert syndrome                                *TMEM237*                   Recessive                   Truncation                                 \[[@B54]\]             
  Familial exudative vitreoretinopathy           *TSPAN12*                   Dominant                    Missense                                   \[[@B55]\]             
  **Candidate exome capture**                    Retinal- renal ciliopathy   *SDCCAG8*                   Recessive                                  Truncation mutations   \[[@B56]\]
  ***cis*-Regulatory mapping**                   RP                          *MAK*                       Recessive                                  Truncation mutation    \[[@B57]\]

All of the diseases listed here, except AMD, are monogenic. AMD is a multifactorial and complex disease.

Candidate exome capture
-----------------------

In a slight variation of WES, candidate exome sequencing captures the selected coding regions that are relevant to a specific genetic trait. Consequently, the examination of a smaller genomic region allows better utilization of resources and the analysis of a larger group of patients. This approach has been useful for ciliopathies, where almost 2,500 genes that are implicated in ciliary function can serve as potential candidates \[[@B58]\]. Candidate exome capture of about 13,000 exons from 828 candidate genes recently identified mutations in the *SDCCAG8* gene in patients with retinal-renal ciliopathies \[[@B56]\]. Mutations in a single gene can cause overlapping syndromic phenotypes, and so the candidate exome capture strategy helps in refining genotype-phenotype correlations.

Targeted re-sequencing
----------------------

Mendelian traits have often been mapped using multi-generational families, narrowing the genomic search space for causal gene identification. Owing to the limited number of meiotic crossing-overs, however, linkage intervals can often span several megabases and include tens or hundreds of transcribed sequences. Intelligent guesses to select and sequence candidate genes can lead to labor-intensive and expensive efforts that often provide limited data on the coding regions of annotated genes. NGS can now be used to capture and sequence large genomic regions of interest, expediting the discovery of causal genes (Table [1](#T1){ref-type="table"}).

Whole-genome sequencing
-----------------------

WES, candidate exome capture and targeted re-sequencing can examine only a fraction of the genome and present additional challenges (Table [2](#T2){ref-type="table"}). A role for variants beyond coding regions has occasionally been reported in Mendelian traits, including in vision disorders; for example, intronic mutations in *RP1*\[[@B59]\] and *OFD1*\[[@B53]\] are implicated as causes of RP, and *CSPG2* variants may cause congenital vitreoretinopathies \[[@B60]\]. The inability of WES to assess the impact of non-coding, conserved or regulatory regions, and other long-range genomic alterations has encouraged researchers to move towards whole-genome sequencing (WGS), which is becoming more cost-effective. Nevertheless, progress has been slow because of the technological limitations associated with the analysis and handling of large datasets.

###### 

A comparison of next-generation sequencing methodologies

  **Method**                                              **Advantages**                                                                                                        **Limitations**                                                                                                                                                                                     **Applications**
  ------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  **Whole-exome sequencing or candidate exome capture**   Customized, economical compared to WGS, manageable data size                                                          Captures genetic variants only in the coding regions of the genome; inefficient hybridization step; high DNA input; susceptible to capture bias                                                     SNP and indel discovery in coding exons; suitable for the identification of causal genes in high-penetrance Mendelian diseases
  **Targeted re-sequencing**                              Customized, economical compared to WGS                                                                                Genetic variant discovery is limited by array design; high DNA input; inefficient hybridization step; captures only a small proportion of the genome                                                SNP and indel discovery; suitable for sequencing linkage intervals and genomic regions at or around associated signals
  **Whole-genome sequencing**                             Uncovers genome-wide coding and non-coding variants, no capture bias                                                  Expensive; very large dataset; analysis methods are still evolving                                                                                                                                  Genome-wide SNP, indel and CNV discovery; suitable for rare variant discovery in Mendelian, complex or sporadic traits
  **Exome-chip**                                          Cost-effective method for evaluating known rare variants (MAF of 1 to 5%)                                             Does not identify novel variants; limited to coding region; limited representation of intronic and regulatory variants                                                                              Genome-wide association analysis with rare variants
  **RNA-Seq**                                             Array-independent profiling of the transcriptome                                                                      High coverage required for the identification of low-copy transcripts; not applicable for the identification of variants that cause loss of protein; limited by tissue- or cell-type availability   Genome-wide expression profiling; alternative transcript identification; non-coding RNA detection; SNP profiling; eQTL analysis
  **ChIP-Seq**                                            Genome-wide profiling of epigenetic marks (DNA methylation and histone modifications) and *cis*-regulatory elements   Dependent on the quality of antibody; requires high input; analysis methods still evolving; high coverage needed for accurate profiling                                                             DNA methylation; histone modifications; tissue-specific enhancer profiling

RNA-Seq or transcriptome sequencing
-----------------------------------

The transcriptome represents a collection of all transcribed sequences (RNAs), both protein-coding and non-coding, in a cell type or particular tissue and at a specific stage of development or age. While microarray technology and methods for serial analysis of gene expression (SAGE) have been valuable, transcriptome profiling using NGS technology (RNA-Seq) is becoming popular because of its ability to survey the transcriptome in a high-throughput and quantitative manner and at low cost \[[@B61]\]. In addition, RNA-Seq has proven useful for annotating protein-coding genes, discovering novel alternatively spliced transcripts and non-coding RNAs (ncRNAs), single nucleotide polymorphism (SNP) profiling, and the detection of gene fusions or rearrangements \[[@B62]\]. DNA-Seq approaches generate a large number of variants and often secondary filtering is required to prioritize the candidate disease genes. Tissue-specific expression profiles therefore offer a valuable first-level screen to identify relevant disease-causing variants (Figure [2](#F2){ref-type="fig"}).

Profiling of alternative transcripts
------------------------------------

In humans, a majority of genes (\>90%) undergo alternative splicing to generate tissue-specific and functionally diverse protein isoforms \[[@B63]\]. The role of novel transcripts in diverse pathways and disease causation is slowly being recognized \[[@B64],[@B65]\]. Retina-specific isoforms of *RPGR* and *BBS3* have been implicated in X-linked RP and BBS, respectively \[[@B66],[@B67]\]. In addition, mutations in the spliceosome-component genes (*PRPF31*, *PRPF3*, and *PRPF8*) are associated with RP \[[@B68]\]. Thus, retina-specific RNA or transcriptome profiling provides an excellent opportunity to identify novel functionally relevant transcripts. As novel transcripts may be present at low-copy number, RNA CaptureSeq (Box 1) can provide an alternative approach for enrichment \[[@B69]\].

Non-coding RNA
--------------

ncRNAs appear to play prominent and diverse roles in normal development, physiology, and disease. Several specific microRNAs (miRNAs) are expressed in the retina (miR-96, miR-182, and miR-183) \[[@B70],[@B71]\] and RPE (miR-204/211) \[[@B72]\]. Long antisense (non-coding) transcripts have been associated with eight transcription factors that are involved in eye development \[[@B73]\], and two ncRNAs, *TUG1*\[[@B74]\] and *Six3OS*\[[@B75]\], have been linked to retinal differentiation. Inactivation of *DICER1*, an RNase III endonuclease that is essential for the production and function of mature miRNAs, has been implicated in retinal degeneration \[[@B76]\], and Alu RNA toxicity has been suggested to a play a role in AMD \[[@B77]\]. Thus, further exploration of ncRNAs seems essential, and RNA-Seq offers a starting point for the identification of novel ncRNAs in development and disease.

SNP profiling
-------------

Genetic variations within the transcribed (coding or non-coding) regions of the genome can alter the expression or function of the encoded sequence. Therefore, RNA-Seq can provide profiles of genetic variants in both the quasi-complete set of transcribed genes (mRNAs) and ncRNAs in a cost-effective manner and without the need for target-probe hybridization, a necessary but inefficient step in capture-based methods. However, RNA-Seq should be applied with caution, as it is possible to miss variants that result in the loss of a gene product.

ChIP-Seq-based approaches
-------------------------

The genomic location and function of regulatory elements contributes significantly to the development of human diseases. Chromatin immunoprecipitation followed by NGS (ChIP-Seq) can be used to profile *cis*-regulatory elements (CREs) (Box 1), which include transcription factor binding sites clustered within promoters, enhancers and silencers \[[@B78]\]. ChIP-Seq has been employed to generate genome-wide maps of CREs for two key photoreceptor-specific transcription factors, *CRX*\[[@B79]\] and *NRL*\[[@B80]\]. In addition, these data have permitted the prioritization of disease-associated genes or variants for further study. Not surprisingly, several *CRX* and *NRL* target genes are associated with RDDs \[[@B79],[@B80]\], and recently, *CRX* ChIP-Seq data were used to filter the candidates to identify mutations in *MAK* (encoding a regulator of ciliary length) as a cause of autosomal recessive RP \[[@B57]\].

ChIP-Seq can also be employed for genome-wide profiling of epigenetic modifications, such as DNA methylation and covalent modifications of histones \[[@B81]\]. Epigenetic variations can influence gene expression and developmental programming \[[@B82],[@B83]\]. Evidence suggests the involvement of epigenetic mechanism in RDDs; but such modifications are more likely to be associated with complex disorders, such as AMD \[[@B84]\], glaucoma and diabetic retinopathy. Epigenetic profiling of retina, RPE and other eye tissues or cells, in combination with gene profiling, should provide valuable insights into disease mechanisms. The Encyclopedia of DNA Elements (ENCODE) project has systematically integrated gene expression data with information on regulatory elements, transcription factor binding, and epigenetic modifications for as much as 80% of the genome \[[@B85]\]. Expression profiles and other data relevant to retinal and macular diseases have not, however, been incorporated as yet.

NGS approaches for complex traits
=================================

The identification of the genetic susceptibility variants underlying complex multifactorial disorders requires extensive efforts including large patient cohorts and cumbersome analytical tools. GWAS have been successful in uncovering associated loci for numerous diseases, but such studies only examine common (tagging) variants in populations and additional investigations are necessary to identify causality. In this section, we provide an overview of the possible applications of NGS, with an emphasis on the study design for complex diseases.

GWAS and meta-analysis
----------------------

GWAS have begun to unravel the genetic architecture of complex traits. Hundreds of susceptibility loci associated with multifactorial diseases have now been discovered \[[@B86]\]. AMD provided the first example of GWAS success with the identification of *CFH* susceptibility loci \[[@B87]\]. Multiple GWAS and large-scale meta-analysis studies have to date revealed as many as 19 AMD susceptibility loci \[[@B10],[@B88]\]. However, the associated variants are not causal and do not explain a substantial fraction of genetic heritability. Rare and structural variants at these associated susceptibility loci might help to explain the causality and missing heritability \[[@B89]\]. NGS approaches have made the identification of rare alleles feasible and have ushered in a new era for a second-generation of association studies in complex diseases (Figure [3](#F3){ref-type="fig"}).

![**A general workflow for dissecting genetics of complex traits using different NGS methodologies.** Various NGS methods (targeted re-sequencing, exome-chip, whole exome and genome sequencing) can be applied separately or in combination with each other for identification of candidate genes in complex RDDs. Expression and eQTL analysis in retinal tissues can provide the second level of filtering for prioritizing the candidates. Pathway and network analysis can further help in understanding the relationship and interactions among candidates. Ultimately, the functional dissection of candidates would be needed for establishing their roles in disease pathogenesis.](gm488-3){#F3}

Rare variant identification
---------------------------

The hypothesis that rare variants influencing a complex trait should co-localize with associated common alleles has accelerated targeted re-sequencing of the GWAS loci \[[@B90]\]. Such studies have led to the identification of rare coding variants, R1210C in *CFH*\[[@B49]\] and G119R in *CFI*\[[@B12]\], that are associated with AMD. WES studies are also being performed to test the association of rare coding variants with a complex phenotype \[[@B91],[@B92]\]. However, such studies require a large sample size to achieve the statistical power necessary to detect a significant association that can then justify multiple testing. In the absence of such a dataset, extreme phenotype study design, in which samples from both ends of the phenotype distribution are analyzed, can serve as a suitable alternative (Figure [3](#F3){ref-type="fig"}) \[[@B93]\]. In addition, inherited macular dystrophies share common clinical characteristics with AMD, and occasionally genes identified in heritable forms, such as *TIMP3*\[[@B94]\] and *ABCA4*\[[@B95]\], have been associated with AMD \[[@B88],[@B96]\]. Thus, WES and WGS in families with macular dystrophies (and occasionally in available AMD families) can uncover rare variants that might contribute to disease pathophysiology.

Copy number variations
----------------------

Large DNA stretches (\>1 kb) that exhibit variable copy number when compared to the reference genome contribute significantly to population dynamics and evolution. Comparative genomic hybridization (CGH) arrays and SNP arrays have been commonly used to detect copy number variations (CNVs) that are implicated in neurodevelopmental (autism, schizophrenia, and intellectual disability) and immune-related diseases (Crohn's disease, psoriasis, HIV/AIDS, rheumatoid arthritis, and type I diabetes) \[[@B97]\]. The role of CNVs is under investigation in AMD \[[@B98]-[@B100]\]. An 84-kb deletion spanning *CFHR1* and *CFHR3* has been associated with protection against the development of AMD \[[@B101]-[@B103]\]. A recent GWAS has identified CNVs at *NPHP1* and *EFEMP1* as potential candidates for AMD association \[[@B100]\]. CNVs in additional genes, such as *CCR3*, *CFH*, *CX3CR1*, *ERCC6*, *HTRA1*, *VEGF*, *GSTM1*, and *GSTT1*, have also been associated with AMD \[[@B104]\]. Nevertheless, a complete spectrum of CNVs in complex diseases (including AMD) has not been realized yet because of the limited resolution of current methods. NGS-based CNV detection utilizes high-coverage WGS data for unbiased detection of CNVs at much higher resolution than has been available to date, providing information about CNV breakpoints and the location of copy number gains \[[@B105],[@B106]\]. Nevertheless, methodologies for CNV detection using NGS lack well-defined workflows, protocols, and quality-control measures, imposing substantial computational and bioinformatic challenges \[[@B107]\]. In addition, databases for human structural variation are limited and contain inadequate information on most breakpoints. A validated pipeline for structural variation analysis using NGS data is highly desirable for utilizing the full potential of CNVs for complex trait analysis.

Exome-chip
----------

A common-variant-based GWAS approach has not explained the complete genetic variance observed in complex traits. Missing heritability might be explained by rare to low frequency variants (minor allele frequency (MAF) of 1 to 5%) \[[@B90],[@B108],[@B109]\]. NGS studies, such as the 1,000 Genomes Project \[[@B110]\] and the NHLBI Exome Sequencing Project \[[@B111]\], have identified a large number of such variants, leading to a second-generation genotyping array for testing the association of rare variants in complex traits \[[@B112]\]. Ideally, all common GWAS variants that are associated with distinct phenotypes can be included in such exome-chips. Although any regulatory or novel rare variant is not identified by this approach in RDDs, exome chips offer an economical and rapid platform that can be used to test the hypothesis that certain rare variants are causal alleles in common diseases. Such studies are currently in progress as part of a large AMD consortium and should identify novel variants and genes in the near future.

Expression quantitative trait loci analysis
-------------------------------------------

A vast majority of disease-associated SNPs identified in GWAS are reportedly located in non-coding regions of the genome, and their functional role in causing the disease is generally not understood. Arguably, such variants might regulate gene expression and act as expression quantitative trait loci (eQTL) \[[@B113]\]. Combined analysis of genotyping with RNA-Seq data provides a unique opportunity to correlate genetic variations and expression level at disease-associated loci \[[@B114]\]. Expression profiling is more relevant, however, when implemented in disease-affected tissues or cell types. Although little has been reported on the importance of eQTLs in RDDs, the integration of data on modifier and susceptibility variants with the NGS expression data would facilitate the elucidation of complex regulatory networks that can provide insights into novel intervention strategies.

Making sense of the vast amount of NGS data for disease gene identification
===========================================================================

The identification of relevant candidate disease-causing variants from NGS data requires filtering strategies that depend on multiple factors, such as the availability of well-phenotyped patient cohorts, knowledge of the mode of inheritance, and large sample sizes. Computational tools that can predict the impact of a variant on protein function can assist in segregating the deleterious variants from neutral ones \[[@B115]\]. A general guideline for candidate variant identification is provided for Mendelian (Figure [2](#F2){ref-type="fig"}) and complex RDDs (Figure [3](#F3){ref-type="fig"}), but each biological question might require a unique approach. For example, homozygosity and linkage data can complement WES or targeted sequencing in Mendelian RDDs \[[@B30],[@B31],[@B45]-[@B47]\]. Similarly, the integration of GWAS data with rare variant, eQTL or pathway-based analyses can yield meaningful results for complex traits such as AMD. Ultimately, validation of genetic causality would require additional investigations using *in vitro* assays and/or model organisms.

NGS in diagnostics and disease management for RDDs
==================================================

Over 200 genes have been implicated in RDDs, offering an opportunity to clarify etiology, provide prognosis, and calculate associated risk(s). Nevertheless, molecular diagnosis and counseling are complicated by genetic heterogeneity and extensive phenotypic variability. Mutations in the same gene can cause different phenotypes and similar clinical findings can result from mutations in different genes. For example, *RPGR* and *RP2* are primary causative genes in X-linked RP, but recent studies have reported the prevalence of *RP2* and *RPGR* mutations even in simplex retinal degeneration in males \[[@B116]\] and in pedigrees with 'apparent' autosomal dominant inheritance of RP \[[@B117]\]. Thus, the boundaries of distinct clinical entities can be blurred, demanding more comprehensive methods of molecular evaluation \[[@B118]\].

Customized arrays have been developed for screening patients with RP \[[@B119],[@B120]\] and other retinal dystrophies \[[@B121],[@B122]\]. The National Eye Institute has established the National Ophthalmic Disease Genotyping and Phenotyping Network (eyeGENE®), which offers molecular diagnosis as a service \[[@B123]\]. The eyeGENE® network currently includes Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory partners; over 270 registered clinical organizations with 500 registered users from around the United States and Canada have analyzed over 4,400 samples. eyeGENE® is also working towards setting up high-throughput genotyping and sequencing technologies for improved clinical sequencing. These efforts, however, need continuous validation of reliability, robustness and reproducibility of the technology being employed. Implementation of NGS hardware requires substantial in-house infrastructure and a standardized guideline for NGS protocols. Issues related to the ownership and confidentiality of genomic data and the handling of incidental or secondary findings (Box 1) must also be addressed before NGS technology moves into routine clinical practice.

Understanding the biology of disease
====================================

The extreme phenotypic variability in RDDs can be attributed to allelic heterogeneity, modifier loci, and epigenetic and environmental factors, or a combination of these. A modifier gene is predicted to alter the phenotypic outcome of a given genotype by interacting with the primary disease gene or by functioning in the same or a related biological pathway, affecting penetrance, expressivity and pleiotropy \[[@B124],[@B125]\]. A few examples are warranted. Digenic inheritance has been reported for mutations in *ROM1* and peripherin/*RDS* resulting in RP \[[@B126]\] and for *ROM1* and *ABCA4* mutations in macular dystrophy \[[@B127]\]. *CNOT3* can modify the phenotype of a *PRPF31* mutation in RP \[[@B128]\]. The potential involvement of mutations in more than one causative gene has also been described in LCA \[[@B129]\]. Phenotypic differences in ciliopathies are also attributed to modifiers \[[@B130],[@B131]\]. For example, a common allele in *RPGRIP1L*, Ala229Thr, is reported to be a modifier of retinal degeneration in ciliopathy patients \[[@B132]\]. *AHI1* seems to act as a modifier of *CEP290*\[[@B133]\] and *NPHP1*\[[@B134]\], and *PDZD7* can modify the phenotype in Usher syndrome patients who have a homozygous *USH2A* mutation \[[@B135]\]. The search for modifiers has, however, been limited because of their non-Mendelian segregation and restricted exploration within known RDD genes, and because of the abundant normal genetic variations in humans. NGS approaches offer an expanded platform for genome-wide evaluation of modifier variants that would permit a better understanding of phenotypic variability and progression in RDDs.

Mouse models have provided valuable insights into RDD pathogenesis, but complex interactions among retinopathy proteins and additional variants can exacerbate or ameliorate the disease phenotypes. For example, mice that had a combination of *Cep290* and *Mkks* disease alleles had better sensory functions than those with either mutation alone \[[@B136]\]. The development of therapeutic strategies would therefore require a comprehensive understanding of RDD gene interaction networks and cellular pathways. NGS technology should expedite the integration of genetic variants in relevant RDDs and modifier genes with retinal transcriptome and epigenetic profiles.

Conclusions, challenges and future prospects
============================================

It is an exciting time in the genetic analysis of RDDs as NGS has led to unprecedented access to various genome-wide datasets. NGS has proven successful in identifying the genetic cause of monogenic RDDs in many patients and families and offers great promise for the genetic dissection of complex RDDs. With the generation and analysis of NGS data becoming more accessible and affordable, a comprehensive catalog of variants for most (if not all) vision-related traits seems a viable prospect. Whole-transcriptome and epigenome analysis in retinal tissues would greatly facilitate the elucidation of important pathways or networks underlying development and disease. In this review, we have highlighted the challenges and the opportunities in applying NGS for gene discovery and clinical diagnosis of RDDs. A major goal lies ahead in developing a unified framework for identifying all disease-relevant variants and genes. Methods for downstream bioinformatic analyses are still evolving and represent a major bottleneck in NGS applications. There is significant room for improvement in mapping and variant-calling methods, especially for small insertions or deletions and CNVs. Better tools are required for combining information from across studies that have used different sequencing platforms or even distinct methods of data analysis. As each kind of NGS data has its own merits, integrated and multidimensional analyses of biological systems with relevant clinical information records would be valuable for intervention and personalized medicine.

Box 1. Glossary
===============

**Next-generation sequencing (NGS):** also known as massively parallel sequencing or high-throughput sequencing; these recent technologies allow parallel sequencing of multiple samples and produce millions of sequence reads concurrently, thereby reducing the sequencing costs and time considerably.

**Mendelian disease:** also called monogenic disease; results from single genetic defect(s) that are passed on to the next generation in a Mendelian inheritance pattern (dominant, recessive, or X-linked).

**Complex disease:** a multifactorial disease that does not exhibit a simple Mendelian inheritance pattern and is caused by complex interplay among genetic, epigenetic and environmental factors.

**Simplex case:** also known as sporadic cases; those in which only a single individual has a clinical diagnosis and no relatives are affected.

**Whole-genome sequencing (WGS):** sequencing of the complete DNA of an organism's genome.

**Whole-exome sequencing (WES):** capture and sequencing of the coding exons of all genes, comprising roughly 1 to 2% of the genome.

**Targeted re-sequencing:** sequencing of a defined (targeted) region of the genome; helpful in identifying disease variant(s) when a linkage region has been established.

**Transcriptome:** the complete set of coding and non-coding transcripts (RNAs) expressed in a specific cell type, tissue or organism.

**RNA-Seq:** sequencing of transcriptome using NGS; RNA-Seq includes only the transcribed sequences of the genome.

**RNA CaptureSeq:** use of tiling arrays to capture and sequence selected portions of the transcriptome.

**Chromatin immunoprecipitation (ChIP):** a method for investigating the genomic DNA region(s) that are interacting with a protein *in vivo,* by capturing the DNA that is bound to a specific antibody.

**ChIP-Seq:** combines ChIP with NGS to generate a genome-wide map of DNA-binding proteins; can be used to identify genome-wide epigenetic marks on histones.

***cis*-Regulatory element (CRE):** DNA sequence in or near a gene (in *cis*) containing binding sites for transcription regulatory proteins that control the spatiotemporal expression of the target gene.

**Single-end sequencing:** sequencing of a DNA molecule only from one end; as NGS reads can be small, single-end sequencing might not be efficient in mapping low complexity and repetitive regions of the genome.

**Paired-end sequencing:** sequencing of a DNA molecule from both ends, resulting in a superior alignment across the genome.

**Mapping sequence assembly:** mapping of NGS reads to a reference genome.

***De novo*assembly:** a method of generating large assemblies of NGS reads in the absence of a reference genome.

**Single nucleotide polymorphisms (SNPs):** genetic variations that alter a single nucleotide in the genome.

**Insertion-deletion variation (indel):** any sequence change that leads to the addition or removal of one or more nucleotides compared to the reference genome.

**eQTL analysis:** analysis of genomic loci that have statistically significant correlation between genotype and gene expression levels, and thus regulate gene expression levels.

**Copy number variation (CNV):** a segment of DNA (\>1 kb) that is present at a variable copy number compared to the reference genome, altering the diploid status at a particular locus.

**Deleterious variant:** a DNA change that lowers the fitness of the gene by altering the expression or function of the encoded protein or RNA and remains under the selection of various strengths.

**Neutral variant:** a variant that does not alter the function of a gene or confer any influence on the fitness of a gene.

**Conserved variant (or conserved residue):** a DNA nucleotide or amino acid residue that shares identity among closely related species.

**Private variant:** a genetic variant that is confined to a single individual or a family.

**Incidental or secondary findings:** refers to the identification of any genetic finding that has health or reproductive relevance for the patient, but was not obtained as a part of the original goals of the study.

Box 2. Next-generation sequencing methods
=========================================

**Next-generation sequencing:** also known as massively parallel sequencing or high-throughput sequencing, this process enables the sequencing of a large number of DNA sequences in a single reaction; NGS has revolutionized the genomics field by producing fast, inexpensive and accurate sequencing data.

**Platforms:** several NGS platforms are commercially available, including Roche/454, Illumina/Solexa, ABI SOLiD, Life/APG, Helicos BioSciences and Pacific Biosciences; Illumina is a widely used platform because it provides large throughput at low cost.

**Template preparation:** starting material (genomic DNA, cDNA or immuno-precipitated DNA) is sheered to small-size fragments of 30 to 400 base pairs and ligated to a universal adapter. DNA can then be amplified using emulsion PCR or bridging amplification, followed by sequencing, or in the case of single molecule templates, sequenced directly.

**Sequencing reaction:** NGS chemistry methods (cyclic reversible termination, sequencing by ligation, pyrosequencing and real-time sequencing) vary among different platforms; sequencing by synthesis (SBS) is a commonly used approach that includes the use of DNA polymerase or DNA ligase for stepwise nucleotide addition.

**Output:** high throughput is a key feature of NGS protocols, with a single run producing several gigabases (Gb) of sequence data. Output varies among platforms; for example, Illumina HiSeq 2000 produces 95 to 600 Gb and SoLiD/ABI 5500 produces 90 to 300 Gb in a single run.

**Assembly and mapping:** once sequencing is accomplished, the initial analysis of base calling is performed by proprietary software on the sequencing platform, followed by aligning the data to a known reference genome if available or by *de novo* assembly; short read lengths can make mapping in the repetitive regions challenging.

**Analysis:** downstream analysis varies depending on the biological question; DNA-Seq data are subjected to variant and CNV detection, whereas RNA-Seq data are used to characterize the transcriptome and ChIP-Seq is used for large-scale analysis of chromatin features.

Abbreviations
=============

AMD: Age-related macular degeneration; BBS: Bardet-Biedl syndrome; ChIP: Chromatin immunoprecipitation; CNV: Copy number variation; CRE: *cis*-regulatory element; eQTL: Expression quantitative trait loci; GWAS: Genome-wide association studies; L: Long wave-length; LCA: Leber congenital amaurosis; M: Medium wave-length; MAF: Minor allele frequency; miRNA: microRNA; ncRNA: Non-coding RNAs; NGS: Next-generation sequencing; RDD: Retinal degenerative diseases; RP: Retinitis pigmentosa; RPE: Retinal pigment epithelium; S: Short wave-length; SNP: Single nucleotide polymorphism; WES: Whole-exome sequencing; WGS: Whole-genome sequencing.
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